A Shift from Diabetic Clinical Therapy to Aesthetic Use: The Ozempic Phenomenon

Background: Ozempic is a GLP-1 receptor agonist indicated for the treatment of T2DM. However, its effectiveness in suppressing appetite and reducing weight has led to increased off-label use by non-diabetic individuals, especially for aesthetic purposes. These changing patterns of use have raised concerns about long-term side effects, misuse, and a crisis of access to medication for diabetes patients who need it. Purpose: This article examines the transformation of Ozempic from a metabolic therapy drug to an aesthetic accessory, driven by the virality of social media content. This phenomenon not only triggers therapeutic exclusion for diabetic patients, but also opens ethical discussions about drug distribution, pharmaceutical commercialization, and the risks of using outside medical indications. Method: This study conducted a literature review of recent articles, reports, and relevant publications related to the adverse effects and distribution disparities of Ozempic. Results: Data shows a 594% increase in global use of GLP-1RAs between 2020 and 2023, with a 659% increase in women aged 18 - 25 and a 481% increase in men. Ozempic sales are expected to surge 26% in 2024 to $40.5 billion for Novo Nordisk, and 32% to $45 billion for Eli Lilly. This surge coincides with reports of Ozempic shortages, which have a direct impact on high-risk T2DM patients. Conclusion: The use of Ozempic outside of medical indications shows the need for strict regulation, balanced public education, and equitable distribution of drugs. Without intervention, this trend could worsen therapeutic exclusion and shift the function of essential drugs into aesthetic commodities.